Compugen Still Confident Of Its TIGIT Strategy Despite Roche’s Setbacks

Highlights Triple Blockade Strategy And Differentiated TIGIT Molecule

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.